CPR builds on the proprietary antibody engineering technology developed by the Chugai Group in order to achieve our goals.

T-Cell Redirecting Antibody

Chugai has multiple TRAB projects targeting various tumour antigens (TAs) in the discovery research pipeline such as CD3 bispecific antibodies which target against novel tumour antigens, using FAST-IgTM with non-common light chain to accelerate research.

Chugai has combined costimulatory signal to improve anti-tumour efficacy of TRAB. This involves the combination of costimulatory signal with TA/CD137 bispecific.

Chugai has also incorporated Switch Antibody technology to improve the safety profile of TRAB Tumour antigen expressed in normal tissue leads to toxicity. The ATP dependent tumour antigen binding to avoid normal tissue toxicity.

< Back